公开(公告)号：EP1365765B1

公开(公告)日：2007-07-25

申请号：EP02722637.2

申请日：2002-01-09

申请人： Bayer Schering Pharma Aktiengesellschaft

发明人： HEGELE-HARTUNG, Christa ,  HESS-STUMPP, Holger ,  BEIER, Henning, M. ,  KRUSCHE, Claudia

IPC分类号： A61K31/567 ,  A61P15/00

CPC分类号： A61K31/57 ,  A61K31/567

摘要： A method of inhibiting the occurrence of advanced endometrium maturation in a female mammal undergoing fertility treatment is disclosed. The method comprises the administration at least one 17 alpha -fluoralkylated progesterone receptor antagonist to the female mammal.

公开(公告)号：EP1272504B1

公开(公告)日：2007-05-30

申请号：EP01931609.0

申请日：2001-04-12

申请人： Bayer Schering Pharma Aktiengesellschaft

发明人： PETERS, Olaf ,  HILLISCH, Alexander ,  THIEME, Ina ,  ELGER, Walter ,  HEGELE-HARTUNG, Christa ,  KOLLENKIRCHEN, Uwe ,  FRITZEMEIER, Karl-Heinrich ,  PATCHEV, Vladimir

IPC分类号： C07J1/00 ,  A61K31/565 ,  C07J41/00 ,  A61P5/30

CPC分类号： C07J1/007 ,  C07J1/0059 ,  C07J1/0062 ,  C07J1/0074 ,  C07J41/0072

摘要： The invention relates to novel 8ß-substituted estratrienes of the general formula (I), wherein R?2, R3, R6, R6', R7, R7', R9, R11, R11', R12, R14, R15, R15', R16, R16', R17 and R17'¿ are defined as in the description and R8 represents a straight- or branched-chained, optionally partially or completely halogenated alkyl or alkenyl group with up to 5 carbon atoms, an ethinyl or prop-1-inyl group. The inventive estratrienes are used as pharmaceutically active substances that have in vitro a higher affinity to estrogen receptor preparations of rat prostate than to estrogen receptor preparations of rat uterus and which in vivo preferably have a preferential effect on bone material as compared to uterus and/or a pronounced effect with respect to the stimulation of the expression of 5HT2a receptor and transporter. The invention further relates to the production of these novel compounds, to their use in therapy and to the pharmaceutical forms of administration that contain said novel compounds. The invention further describes the use of said compounds for treating estrogen-deficiency related diseases and conditions and to the use of an 8ß-substituted estratriene structural part in the overall structures of compounds that are characterized by a dissociation in favor of their estrogen effect on the bone as compared to the uterus.

公开(公告)号：EP1689410B1

公开(公告)日：2008-05-21

申请号：EP04803177.7

申请日：2004-11-16

申请人： Bayer Schering Pharma Aktiengesellschaft

发明人： HEGELE-HARTUNG, Christa ,  FRITZEMEIER, Karl-Heinrich ,  PETERS, Olaf ,  PELZER, Theo ,  NEYSES, Ludwig

IPC分类号： A61K31/565 ,  A61P9/00 ,  A61P9/02 ,  A61P9/04 ,  A61P9/08 ,  A61P9/10 ,  A61P9/12

CPC分类号： A61K31/565

摘要： The present invention relates to the use of the ERb agonists 8b-Vinyl-estra-1,3,5(10)-trien-3,17b-diol and 17b-Fluor- 9a-vinyl-estra-1,3,5(10)-trien-3,16a-diol for production of medicaments for the prevention and/or treatment of hypertensive heart disease, especially for the prevention and/or treatment of one or more of the conditions selected from the group of (1) hypertension, (2) cardiac hypertrophy and (3) heart failure.

公开(公告)号：EP1365768B1

公开(公告)日：2008-05-07

申请号：EP02706750.3

申请日：2002-02-27

申请人： Bayer Schering Pharma Aktiengesellschaft

发明人： HEGELE-HARTUNG, Christa ,  FRITZEMEIER, Karl-Heinrich ,  YAMANOUCHI, Hiroshi ,  PETERS, Olaf ,  KOSEMUND, Dirk ,  MUELLER, Gerd ,  TORNUS, Ingo ,  SCHUBERT, Gerd ,  RING, Sven

IPC分类号： A61K31/57 ,  A61K31/565 ,  A61K31/00 ,  C07J63/00

CPC分类号： A61K31/00 ,  A61K31/05 ,  A61K31/122 ,  A61K45/06

摘要： The present invention discloses the use of ERSS-selective ligands for production of medicaments for regulating fertility without additional use of a progestin. ERSS-agonists are used for treatment of infertility and ERSS-antagonists for contraception.